Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis.
In: Journal of Neurology, Neurosurgery & Psychiatry, Jg. 92 (2021-03-01), Heft 3, S. 295-302
academicJournal
Zugriff:
Objective: To establish a rigorous, expert-led, evidence-based approach to the evaluation of licensed drugs for repurposing and testing in clinical trials of people with progressive multiple sclerosis (MS). Methods: We long-listed licensed drugs with evidence of human safety, blood-brain barrier penetrance and demonstrable efficacy in at least one animal model, or mechanistic target, agreed by a panel of experts and people with MS to be relevant to the pathogenesis of progression. We systematically reviewed the preclinical and clinical literature for each compound, condensed this into a database of summary documents and short-listed drugs by scoring each one of them. Drugs were evaluated for immediate use in a clinical trial, and our selection was scrutinised by a final independent expert review. Results: From a short list of 55 treatments, we recommended four treatments for immediate testing in progressive MS: R-α-lipoic acid, metformin, the combination treatment of R-α-lipoic acid and metformin, and niacin. We also prioritised clemastine, lamotrigine, oxcarbazepine, nimodipine and flunarizine. Conclusions: We report a standardised approach for the identification of candidate drugs for repurposing in the treatment of progressive MS. [ABSTRACT FROM AUTHOR]
Copyright of Journal of Neurology, Neurosurgery & Psychiatry is the property of BMJ Publishing Group and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis.
|
---|---|
Autor/in / Beteiligte Person: | Cunniffe, Nick ; Vuong, Khue Anh ; Ainslie, Debbie ; Baker, David ; Beveridge, Judy ; Bickley, Sorrel ; Camilleri, Patrick ; Craner, Matthew ; Fitzgerald, Denise ; de la Fuente, Alerie G. ; Giovannoni, Gavin ; Gray, Emma ; Hazlehurst, Lorraine ; Kapoor, Raj ; Kaur, Ranjit ; Kozlowski, David ; Lumicisi, Brooke ; Mahad, Don ; Neumann, Björn ; Palmer, Alan |
Zeitschrift: | Journal of Neurology, Neurosurgery & Psychiatry, Jg. 92 (2021-03-01), Heft 3, S. 295-302 |
Veröffentlichung: | 2021 |
Medientyp: | academicJournal |
ISSN: | 0022-3050 (print) |
DOI: | 10.1136/jnnp-2020-324286 |
Schlagwort: |
|
Sonstiges: |
|